Clinical Characteristics, Treatments, and Outcomes of MI Patients Presenting With Normal ECG

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04710446

Enrollment

200

Registered

2021-01-14

Start date

2018-01-01

Completion date

2023-01-31

Last updated

2022-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrocardiography, Non-ST Elevated Myocardial Infarction

Keywords

Clinical Characteristics, Treatments, Outcomes, normal ECG

Brief summary

the investigators aimed to analyzed data for hospitalized MI patients with normal ECG.

Detailed description

The electrocardiogram (ECG) at presentation is a useful tool for risk prediction. Patients with ACS（Acute Coronary Syndromes） and ST-segment depression on ECG have a worse prognosis than patients with a normal ECG. ST-segment depression is not only a qualitative marker, but also a quantitative marker of risk, because the number of leads with ST-segment depression and the magnitude of ST-segment depression (either within a single lead or as sum over all leads) are indicative of the extent of ischaemia and correlate with prognosis.The presence of ST-segment depression \>1 mm in \>\_6 leads in conjunction with ST-segment elevation in aVR and/or V1, particularly if the patient presents with haemodynamic compromise, suggests multivessel ischaemia or severe left main coronary artery stenosis. However,in patients presenting without persistent ST-segment elevation,the clinical features, treatments, and outcomes in patients with normal ECG is still unclear.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Inclusion criteria

all patients hospitalized with a principal diagnosis of non-ST-segment elevation infarction (NSTEMI) according to the current ACC/AHA guidelines.

Exclusion criteria

end-stage organic disease, thrombotic hematological disorders, and poor echogenicity

Design outcomes

Primary

Measure	Time frame	Description
MACE within 2 weeks	within 2 weeks	Major Adverse Cardiovascular Events within2 weeks
MACE within 1 year	within 1 year	Major Adverse Cardiovascular Events in-hospital within 1 year

Countries

China

Contacts

Primary Contactqiongya Guo

gqy19870203@163.com18838067197

Backup Contactminghu Zhao

634851967@qq.com13603996609

Outcome results